Advertisement
Screener

Adial Pharmaceuticals, Inc. (ADIL) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

1.7 / 5 stars · 15/45 Roast Me

Adial Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

Adial Pharmaceuticals, Inc. (ADIL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 170.42 thousand shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-14

  • Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 170.42K shares, a 4364.66% increase year-over-year.
  • Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-06-30 was 3.82K shares.
  • Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-03-31 was 23.97K shares.
  • Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 1.24K shares, a 136.12% increase from fiscal 2024.
  • Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 526.00 shares, a 99.13% decline from fiscal 2023.
  • Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 60.28K shares, a 50.70% increase from fiscal 2022.
  • Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 40.00K shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in PeriodShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month
2026-06-30170.42K shares
10-Q · filed 2026-08-14
2025-12-311.24K shares
10-K · filed 2026-03-05
2025-06-303.82K shares
10-Q · filed 2025-11-13
27.79K shares
derived: sum of 2 quarters · filed 2025-11-13
2025-03-3123.97K shares
10-Q · filed 2025-11-13
2024-12-3113.22K shares
10-K · filed 2025-03-04
526.00 shares
10-K · filed 2026-03-05
2023-12-3160.28K shares
10-K · filed 2025-03-04
2022-12-3140.00K shares
10-K · filed 2024-04-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92
Scienture Holdings, Inc. (SCNX)United States$0.012B-0.38
KIORA PHARMACEUTICALS INC (KPRX)United States$0.012B
BIOVIE INC. (BIVI)United States$0.012B
Dare Bioscience, Inc. (DARE)United States$0.011B
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
Tempest Therapeutics, Inc. (TPST)United States$0.013B
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36
Moleculin Biotech, Inc. (MBRX)United States$0.011B
MetaVia Inc. (MTVA)United States$0.011B-0.65